Brickell Biotech to sell additional $15M worth of stock as critical clinical trial begins
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) is planning to raise an additional $15 million via new stocks and warrants […]
Source: BizWest
Related Articles
BizWest celebrates 40 years covering business and recognizes 40 iconic leaders who inspired the region’s development.
View related stories: Click here to view the 40th Anniversary supplement. ‘Turnpike’ helps define how economy has changed Wood: Preserving…
Biotechnology boom
The COVID-19 pandemic — and its seemingly never-ending aftermath — has been a nightmare for commercial landlords of many different…
Auddia offers around 6 million shares of common stock
BOULDER – Auddia Inc. (Nasdaq: AUDD), a Boulder-based audio and podcast technology company, has filed with the Securities and Exchange…
Brickell Biotech launches brand reset amid positioning pivot
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI), a clinical-stage pharmaceutical company, has launched a new brand, logo and website as…
A new Foothills — again
FORT COLLINS — The new owners who want to revitalize midtown Fort Collins’ half-century-old Foothills mall say they envision “a…